Skip to content

Dossier · TIC · Dormant

TIC · TIC Solutions, Inc · Stock research

Last analysed ·

Current thesis

Post-merger re-rate: engineering/geospatial backlog hit a record $1.18B (+20% YoY) on 2026-08-06 while legacy inspection fell ~5.5% combined, and UBS's 2026-08-11 upgrade (Buy, PT $12.50 from $11.00) prices an inflection that Q2's +2.5% organic growth has not yet shown. RSI 79.5 at the 2026-08-14 close of $9.85, with no company catalyst inside 30 days.

Invalidation trigger

A daily close below $9.00 erases most of the post-2026-08-06 advance. Secondary: Inspection & Mitigation failing to return to growth at the Q3 print (~2026-11-05 est.) after a ~5.5% combined decline in Q2, or FY2026 revenue tracking under the $2.15B guide low end.

Thesis status

Open commitment scored if the trigger above fires How this is scored →

Latest analysis and events for TIC —

As of 2026-08-15, orbyd's latest analysis for TIC Solutions, Inc (TIC): Post-merger re-rate: engineering/geospatial backlog hit a record $1.18B (+20% YoY) on 2026-08-06 while legacy inspection fell ~5.5% combined, and UBS's 2026-08-11 upgrade (Buy, PT $12.50 from $11.00) prices an inflection that Q2's +2.5% organic growth has not yet shown. RSI 79.5 at the 2026-08-14 close of $9.85, with no company catalyst inside 30 days.

Invalidation trigger: A daily close below $9.00 erases most of the post-2026-08-06 advance. Secondary: Inspection & Mitigation failing to return to growth at the Q3 print (~2026-11-05 est.) after a ~5.5% combined decline in Q2, or FY2026 revenue tracking under the $2.15B guide low end.

Current Thesis

The leg on offer is a post-merger inflection. TIC Solutions is the renamed Acuren Corporation, which closed its acquisition of NV5 Global on 2025-08-04. The 2026-08-06 Q2 2026 report (quarter ended 2026-06-30) split cleanly: legacy Inspection & Mitigation revenue of $296.7M fell roughly 5.5% combined, while Consulting & Engineering revenue of $206.6M rose roughly 16.8% and the combined Consulting & Engineering plus Geospatial backlog reached a record $1.18B, +20% YoY. On 2026-08-11 UBS upgraded to Buy from Neutral and raised its target to $12.50 from $11.00, arguing pro-forma growth accelerates to 5–6% in 2H26 and 2027 against Street estimates of 4–5%, with Inspection & Mitigation returning to growth in Q3. Price has moved on that forecast; the reported number was +2.5% organic and +3.3% combined. The 2026-08-14 close of $9.85 carries an RSI(14) of 79.5 while sitting 32.0% under the 52-week high of $14.49, and there is no company-scheduled event inside the next 30 days to settle the argument.

Life-cycle: ACCELERATING, dated by the 2026-08-06 print and the 2026-08-11 UBS upgrade — fresh sell-side conversion, expanding participation (Investing.com noted a ~24% one-week gain to $10.33 on 2026-08-11). The qualifier is that the acceleration is so far in the narrative and the backlog line, and price is repairing a broken chart rather than making highs.

Bullish and bearish views on TIC Solutions, Inc

The model's bull view on TIC Solutions, Inc (TIC), in brief: Record backlog of $1.18B in Consulting & Engineering plus Geospatial, +20% YoY, disclosed 2026-08-06 — the forward book, and the segment carrying a 47.2% adjusted gross margin (up 70bps YoY). The bear view: Underlying growth is small: +2.5% organic and +3.3% combined in Q2 2026. Both cases follow in full.

Bull Case

  • Record backlog of $1.18B in Consulting & Engineering plus Geospatial, +20% YoY, disclosed 2026-08-06 — the forward book, and the segment carrying a 47.2% adjusted gross margin (up 70bps YoY).
  • Consulting & Engineering revenue $206.6M in Q2 2026, ~+16.8% combined — the acquired side is compounding while the legacy side contracts, which mixes margin upward.
  • Adjusted EBITDA $94.8M at a 16.2% margin in Q2 2026, and the FY2026 outlook of $2.15–2.25B revenue / $330–355M adjusted EBITDA was left unchanged on 2026-08-06 despite the GAAP miss.
  • UBS (2026-08-11) underwrites Inspection & Mitigation returning to growth in Q3 2026, which would flip the segment that produced the ~5.5% decline; the upgrade lifted the target to $12.50 from $11.00, four days after Baird raised its target to $10 from $9.50 on 2026-08-07.
  • NV5 cost-synergy target raised to $25M by mid-2027 from $20M per Q2 call commentary — self-help earnings independent of end-market volume.
  • $15.7M of stock repurchased in 1H 2026 and liquidity of $473.5M including $362.4M cash as of 2026-06-30.

Bear Case

  • Underlying growth is small: +2.5% organic and +3.3% combined in Q2 2026. The headline +86% YoY revenue is the NV5 acquisition entering the base period.
  • GAAP diluted loss of $(0.06) against a $(0.01) consensus (2026-08-06); adjusted diluted EPS was $0.14, so the reported result depends heavily on add-backs.
  • The FY2026 revenue range of $2.15–2.25B was held unchanged and sits below the $2.293B consensus flagged in coverage on 2026-08-06 — the guide is a ceiling on 2026 upside, not a source of it.
  • Inspection & Mitigation adjusted gross margin slipped to 28.3%, down 50bps; the Q3 recovery in that segment remains a forecast.
  • $1.6B of term loan debt against $362.4M of cash constrains what a slower conversion of backlog would do to equity value.
  • The highest visible target, UBS's $12.50, is still 13.7% below the 52-week high of $14.49 — holders from the highs are supply into any continuation.

Setup & Price Structure

  • 2026-08-14 close $9.85. RSI(14) 79.5, three-month return +9.9%, 32.0% below the 52-week high of $14.49.
  • An RSI near 80 while price sits a third under the annual high describes velocity off a low rather than trend extension. The structure is repair work, not a breakout.
  • Investing.com cited $10.33 on 2026-08-11 after a ~24% week; the 2026-08-14 close sits under that, so the first give-back has already printed.
  • Crowding observables, stated as observables: two target revisions inside five sessions (Baird $10 on 2026-08-07, UBS $12.50 on 2026-08-11); a one-week advance of roughly a quarter of market value into the upgrade; RSI at 79.5. No insider transactions and no equity issuance appear in the filing record reviewed here; the only disclosed share flow is the company's own $15.7M of 1H 2026 repurchases.
  • The $9.00 area is where the post-2026-08-06 advance would be substantially erased.
  • With no company-scheduled event before roughly November, continuation has to come from flow and further sell-side action rather than from data.

Catalyst Calendar (next 30 days)

  • 2026-08-15 to 2026-09-14: no company-scheduled event identified. The reporting cadence — Q1 2026 on 2026-05-06, Q2 2026 on 2026-08-06 — puts the next print outside the window.
  • ~2026-11-05 (est.): Q3 2026 results. Resolves whether Inspection & Mitigation returns to growth as UBS projected on 2026-08-11 and whether FY2026 revenue is tracking inside $2.15–2.25B.

Elapsed catalysts

  • Undated within the window: further broker revisions following the 2026-08-07 and 2026-08-11 actions. None is scheduled. (passed 4d ago)

What Would Change Our Mind

The whole re-rate rests on one event that has not happened: Inspection & Mitigation turning positive after a ~5.5% combined decline in Q2 2026. If the Q3 print (~2026-11-05, est.) shows that segment down again, or FY2026 revenue tracking below the $2.15B low end, the growth-acceleration case UBS bought on 2026-08-11 loses its evidence and the stock is left with +2.5% organic growth and $1.6B of term loan debt. On price, a daily close below $9.00 would erase most of the advance that followed the 2026-08-06 report and leave the upgrade unconfirmed by the tape. A secondary equity or convertible offering into the bounce would also change the read, since it would fund the balance sheet with the very strength the narrative created. If coverage broadens further while organic growth stays under 3%, the label moves from ACCELERATING toward SATURATED.

Correlation Notes

  • Inspection & Mitigation tracks refinery, petrochemical and pipeline turnaround and maintenance budgets — downstream maintenance spend, with little sensitivity to rig counts.
  • Consulting & Engineering and Geospatial track infrastructure, utility and public-sector engineering demand; the closest listed reference points are Tetra Tech and AECOM in the US and the European testing-inspection-certification majors (Bureau Veritas, SGS, Applus).
  • $1.6B of term loan debt against $362.4M cash makes the equity a levered claim on backlog conversion, so it trades with credit conditions more than an asset-light services multiple would suggest.
  • Small-cap liquidity plus a post-merger shareholder base: the 2026-08-11 reaction to a single upgrade shows how much of the move comes from broker actions rather than volume-weighted fundamental flow.

Notes

  • Vendor period labels differ: some feeds tagged the 2026-08-06 release as 'Q4' with 'FY2027' guidance. The company reports it as Q2 2026, quarter ended 2026-06-30, guiding FY2026.
  • NV5 Global closed 2025-08-04, so reported YoY revenue growth (+86% in Q2 2026) is acquisition arithmetic; the combined and organic figures are the comparable ones.
  • GAAP and adjusted EPS diverge widely — $(0.06) versus $0.14 in Q2 2026 — on deal amortization and add-backs. Screening on either alone misstates the business.
  • Balance sheet carried $1.6B of term loan debt against $362.4M of cash and $473.5M total liquidity as of 2026-06-30.
  • The company was renamed from Acuren Corporation; older headlines, datasets and broker notes still file it under Acuren.

Related · shared themes

CNC

Centene Corporation

The 08-12 post-print closing high at $67.07 did not extend: 2026-08-13 closed $66.04, 3.9% under the $68.72 52-week high, RSI 56.5. The $500M par redemption settled 08-13 and no company-dated event falls inside 30 days — CMS certification and a Boston conference around 09-08 are the only marks before Q3 (~2026-10-27, est.). MATURING: six post-print revisions, all raises, consensus $71.67, price now stalling into them.

MEDIUM

HPE

Hewlett Packard Enterprise Company

Second consecutive 52-week high (2026-08-13 close $59.82, RSI 77.8) plus removal of the last Juniper legal tail — Judge Casey Pitts entered the DOJ settlement's final judgment 2026-08-12 over a 13-state AG challenge. Unresolved: whether the $5.9B AI backlog clears the $11.5–12.1B / $0.88–0.93 guide at the 2026-09-02 print, at a price already at the high.

MEDIUM

HUM

Humana Inc.

Margin-over-volume Medicare Advantage reset. The 2026-08-12 reclaim of the 50-day held through the 2026-08-13 close of $384.97, but the ten-action revision wave (07-29 to 08-10) has stopped and no confirmed company event exists before the 2026-09-08/10 conference window. The two highest targets are struck on calendar-2028 EPS, a year Humana does not guide. MATURING.

MEDIUM

IRDM

Iridium Communications Inc

Deal-arb, not an operating story. Three process gates cleared at once: HSR expired 2026-08-12, Rocket Lab filed the S-4 on 2026-08-13, FCC transfer applications went in 2026-08-10. The $27.00 cash plus collared RKLB stock marks $54.00 against the 2026-08-13 close of $49.78, a 7.81% discount; FCC consent and the stockholder vote are what is left.

MEDIUM

See also · stocks to watch